<?xml version="1.0" encoding="UTF-8"?>
<p>Because previously vaccinated horses shed virus without clinical signs, EIV vaccine is useful for reducing clinical signs and reducing virus shed but does not eliminate potential transmission (
 <xref rid="R20" ref-type="bibr">
  <italic>20</italic>
 </xref>,
 <xref rid="R46" ref-type="bibr">
  <italic>46</italic>
 </xref>). In 2003, an outbreak of EIV closely related to the Kentucky sublineage occurred in regularly vaccinated thoroughbred horses in England (
 <xref rid="R47" ref-type="bibr">
  <italic>47</italic>
 </xref>). Before this outbreak, the American strain included in the vaccine was considered sufficient to protect horses. This outbreak helped redefine how antigenic drift reduces the efficacy of EIV vaccinations (
 <xref rid="R47" ref-type="bibr">
  <italic>47</italic>
 </xref>). A study of vaccine containing H3N8 A/eq/Kentucky/98 found &gt;40% of vaccinated ponies shed EIV after experimental challenge with aerosolized EIV, although for fewer days than animals in an unvaccinated control group (
 <xref rid="R46" ref-type="bibr">
  <italic>46</italic>
 </xref>). 
</p>
